12:00 AM
Sep 26, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AG013: Phase Ib data

A single-blind, U.S. Phase Ib trial in 19 patients receiving induction chemotherapy showed that AG013 led to a 35% reduction in the percentage of days with ulcerative OM vs. placebo. Additionally, about...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >